Neuphoria Therapeutics Inc.
NEUP · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $23,954 | $0 | $0 | $278 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1,015 | $993 | $671 | $0 |
| Gross Profit | $22,939 | -$993 | -$671 | $0 |
| % Margin | 95.8% | – | – | 0% |
| R&D Expenses | $13,784 | $14,099 | $13,234 | $16,864 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10,884 | $11,695 | $8,350 | $10,845 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24,667 | $25,794 | $21,584 | $27,709 |
| Operating Income | -$1,728 | -$26,787 | -$22,256 | -$28,601 |
| % Margin | -7.2% | – | – | -10,292% |
| Other Income/Exp. Net | $446 | $3,463 | $40 | -$643 |
| Pre-Tax Income | -$1,283 | -$23,324 | -$22,216 | -$29,243 |
| Tax Expense | -$717 | -$131 | -$569 | -$6,307 |
| Net Income | -$566 | -$23,193 | -$21,647 | -$22,936 |
| % Margin | -2.4% | – | – | -8,253.6% |
| EPS | -0.23 | -0.1 | -0.17 | -0.13 |
| % Growth | -130% | 41.2% | -30.8% | – |
| EPS Diluted | -0.23 | -0.1 | -0.17 | -0.13 |
| Weighted Avg Shares Out | 1,623 | 149,801 | 122,395 | 112,779 |
| Weighted Avg Shares Out Dil | 1,623 | 149,801 | 122,395 | 112,779 |
| Supplemental Information | – | – | – | – |
| Interest Income | $166 | $220 | $323 | $7 |
| Interest Expense | $0 | $0 | $0 | $18 |
| Depreciation & Amortization | $1,015 | $993 | $671 | $1,169 |
| EBITDA | -$268 | -$22,331 | -$21,544 | -$28,027 |
| % Margin | -1.1% | – | – | -10,085.7% |